Boundless Bio, Inc. (BOLD)

Boundless Bio Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Selling, General & Admin	19.45	18	12.16	9.31	6.02
Research & Development	54.28	55.27	42.64	37.16	19.28
Operating Expenses	73.73	73.27	54.8	46.47	25.3
Operating Income	-73.73	-73.27	-54.8	-46.47	-25.3
Interest & Investment Income	8.06	7.89	5.28	0.67	0.1
Other Non Operating Income (Expenses)	-0.02	0.01	0.08	-0.1	-0.01
Pretax Income	-65.69	-65.36	-49.43	-45.9	-25.21
Net Income	-65.69	-65.36	-49.43	-45.9	-25.21
Net Income to Common	-65.69	-65.36	-49.43	-45.9	-25.21
Shares Outstanding (Basic)	22	17	1	1	1
Shares Outstanding (Diluted)	22	17	1	1	1
Shares Change (YoY)	1701.54%	1296.71%	10.77%	27.56%	-
EPS (Basic)	-2.95	-3.85	-40.65	-41.81	-29.29
EPS (Diluted)	-2.95	-3.85	-40.65	-41.81	-29.29
Free Cash Flow	-62.11	-63.38	-47.49	-40.66	-25.28
Free Cash Flow Per Share	-2.79	-3.73	-39.05	-37.04	-29.38
EBITDA	-72.59	-72.18	-53.84	-45.53	-24.62
D&A For EBITDA	1.14	1.09	0.96	0.94	0.68
EBIT	-73.73	-73.27	-54.8	-46.47	-25.3

Updated May 9, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q